en · de · es · pt
peptide-index.peptides5388.com › Data › Analytical And Handling Considerations — 2026 Update

Analytical And Handling Considerations — 2026 Update

By Editorial Desk · published 2026-04-05 · last reviewed 2026-05-23 · Data

A practical reference on HPLC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Sr9009 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderVisual inspection is not sufficient for identity.
SolubilitySoluble in DMSO and ethanolLow solubility in water; stock solutions use organic solvent.
Storage-20°C, desiccated, protected from lightLimits hydrolysis and photodegradation.
Analytical methodHPLC-UV/MSUsed for identity and purity assessment.
SynonymsSR9009, StenabolicNaming varies by supplier.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Related pages on this site

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Supporting material

Enzymes that break down proteins begin with activation of trypsinogen to trypsin. The free trypsin then cleaves the rest of the trypsinogen, as well as chymotrypsinogen to its active form chymotrypsin. Enzymes secreted involved in the digestion of fats include lipase, phospholipase A2, lysophospholipase, and cholesterol esterase. Enzymes that break down starch and other carbohydrates include amylase. These enzymes are secreted in a fluid rich in bicarbonate. Bicarbonate helps maintain an alkaline pH for the fluid, a pH in which most of the enzymes act most efficiently, and also helps to neutralise the stomach acids that enter the duodenum. Secretion is influenced by hormones including secretin, cholecystokinin, and VIP, as well as acetylcholine stimulation from the vagus nerve. Secretin is released from the S cells, which form part of the lining of the duodenum in response to stimulation by gastric acid. Along with VIP, it increases the secretion of enzymes and bicarbonate. Cholecystokinin is released from Ito cells of the lining of the duodenum and jejunum, mostly in response to long-chain fatty acids, and increases the effects of secretin. At a cellular level, bicarbonate is secreted from centroacinar and ductal cells through a sodium and bicarbonate cotransporter that acts because of membrane depolarisation caused by the cystic fibrosis transmembrane conductance regulator. Secretin and VIP act to increase the opening of the cystic fibrosis transmembrane conductance regulator, which leads to more membrane depolarisation and more secretion of bicarbonate.

The ease with which our potatoes lend themselves to all sorts of stews gave me the idea of composing a meal of them, to which I invited several amateurs; and at the risk of being thought to be afflicted with potato mania, I will end this review by describing it: it was a dinner. We were first served two soups, one of mashed potatoes from our roots, the other of a fatty broth, in which the potato bread simmered quite well without crumbling; then came a matelote followed by a dish in white sauce, then another in maitre d'hôtel, and finally a fifth in roux. The second service consisted of five other dishes not less good than the first; first a pâté, a frying, a salad, fritters, and the economic cake of which I gave the recipe; the remainder of the meal was not very extensive, but delicate and good; a cheese, a pot of jam, a plate of cookie, another of tarts, and finally a brioche also of potatoes, made up the dessert; after that we had the coffee, also described above. There were two kinds of bread; the one mixed with potato pulp and wheat flour, fairly represented soft bread; the second, made of potato pulp, with their starch, bore the name of firm dough bread; I would have wished that fermentation had put me in a position to make a drink of our roots, to fully satisfy my guests, and to say with foundation: "Do you like potatoes, we have put them everywhere." Every one was cheerful; and if potatoes are drowsy, they produce on us a very opposite effect.

== Modern medical usage == Apomorphine is used for the management of motor fluctuations in Parkinson's disease, particularly for the treatment of "off" episodes. "Off" episodes are periods during which motor symptoms such as rigidity, bradykinesia, or reduced mobility reemerge as the effects of dopaminergic medications wear off. Apomorphine can provide rapid improvement in motor symptoms. Apomorphine is administered in multiple pharmaceutical formulations. Intermittent subcutaneous injection is used as an acute treatment and has been shown to terminate "off" episodes in individuals with motor fluctuations not adequately controlled with oral therapy. Sublingual formulations have also been shown to be effective as acute treatments of "off" episodes. Continuous subcutaneous infusion of apomorphine using a wearable infusion device is also prescribed for individuals with motor fluctuations. Continuous infusion treatment is used in patients whose symptoms are not adequately controlled with oral or transdermal therapies and has been shown to reduce daily "off" time. Apomorphine is generally used as an adjunct to levodopa-based therapy in patients with Parkinson's disease and motor fluctuations.

Sources: en.wikipedia.org

Notes from published material

For services to the community in Hockley Heath, West Midlands. Josephine Parkin. For services to the community in Wakefield, West Yorkshire. Rachel Frances Parkinson. For services to the community in Whitefield, Greater Manchester during Covid-19. Bryony Emily Kate Peall. For services to the community in Saxmundham, Suffolk during Covid-19. Diana Marian Pearman. For services to the community in Sonning Common, Oxfordshire. Michelle Louise Pearse. Quality and Business Support Manager, Nuclear Decommissioning Authority. For services to Education and to the community in West Cumbria. Pearl Ann Pearson-Brooke. For services to the community in Martham, Great Yarmouth, Norfolk. Doreen May Peck. For services to the community in Ashtead, Surrey. Captain (Rtd) Michael Neville Pemberton. Chief Executive Officer, Building Extraordinary Communities. For services to Regeneration and to the community in Cumbria. Michael James Penston. For services to the community in Southampton, Hampshire, during Covid-19. Betty Philipson. President, City Road Club (Hull). For services to Cycling and to the community in the East Riding of Yorkshire. Bryan Phillips. Volunteer, Irish Guards Association. For services to Armed Forces Charities in Northern Ireland. Malson Phillips. Chair, South Wales Shire Horse Society. For services to Conservation. Sukhdev Singh Phull. Engineer, Department for Transport. For services to Transport Technology and for charitable services through the Ekom Charity Trust. Brian Pilgrim. Lately Whitehall Area Workplace Services Manager, Government Property Agency.

=== Maximum depositional age === Some of the most important information we can get from detrital zircon ages is the maximum depositional age of the referring sedimentary unit. The sedimentary unit cannot be older than the youngest age of the analyzed detrital zircons because the zircon should have existed before the rock formation. This provides useful age information to rock strata where fossils are unavailable, such as the terrestrial successions during Precambrian or pre-Devonian times. Practically, maximum depositional age is averaged from a cluster of youngest age data or the peak in age probability because the youngest U-Pb age within a sample is almost always younger with uncertainty.

In early May 1990, one of the two A&M researchers, Kevin Wolf, acknowledged the possibility of spiking, but said that the most likely explanation was tritium contamination in the palladium electrodes or simply contamination due to sloppy work. In June 1990 an article in Science by science writer Gary Taubes destroyed the public credibility of the A&M tritium results when it accused its group leader John Bockris and one of his graduate students of spiking the cells with tritium. In October 1990 Wolf finally said that the results were explained by tritium contamination in the rods. An A&M cold fusion review panel found that the tritium evidence was not convincing and that, while they couldn't rule out spiking, contamination and measurements problems were more likely explanations, and Bockris never got support from his faculty to resume his research. On 30 June 1991, the National Cold Fusion Institute closed after it ran out of funds; it found no excess heat, and its reports of tritium production were met with indifference. On 1 January 1991, Pons left the University of Utah and went to Europe. In 1992, Pons and Fleischmann resumed research with Toyota's IMRA lab in France. Fleischmann left for England in 1995, and the contract with Pons was not renewed in 1998 after spending $40 million with no tangible results. The IMRA laboratory stopped cold fusion research in 1998 after spending £12 million. Pons has made no public declarations since, and only Fleischmann continued giving talks and publishing papers.

Sources: en.wikipedia.org

Background from the literature

reporter In genetic engineering, a gene which when properly expressed encodes a gene product that is easily detected or visualized with biochemical assays (e.g. green fluorescent protein, β-galactosidase, chloramphenicol O-acetyltransferase, etc.), allowing researchers to use its expression in order to study the functions and properties of associated regulatory sequences. Reporters are commonly cloned into plasmid vectors in proximity to putative promoters, enhancers, or response elements, which are then mutated in order to precisely identify the specific recognition motifs within these sequences that are necessary for expression. In the broadest sense, reporters may also include things like molecular tags, fluorescent labels, and hybridization probes which render their conjugated molecules conspicuous or able to be purified; or they may be used similarly to selectable markers, to distinguish cells that express a given product from those that do not, so that researchers can easily identify mutants of interest or verify the success of an experimental treatment or laboratory procedure.

where arg(x,y) is the clockwise angle between the X-axis and the vector (x,y); a function that is available in many programming languages as atan2(y,x). Conversely, given c and α, one can get the type (n,m) by the formulas:

This type of specificity is sensitive to the substrate's optical activity of orientation. Stereochemical molecules differ in the way in which they rotate plane polarized light, or orientations of linkages (see alpha, beta glycosidic linkages). Enzymes that are stereochemically specific will bind substrates with these particular properties. For example, beta-glycosidase will only react with beta-glycosidic bonds which are present in cellulose, but not present in starch and glycogen, which contain alpha-glycosidic linkages. This is relevant in how mammals are able to digest food. For instance, the enzyme Amylase is present in mammal saliva, that is stereo-specific for alpha-linkages, this is why mammals are able to efficiently use starch and glycogen as forms of energy, but not cellulose (because it is a beta-linkage).

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

How should SR9009 be stored?

The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.

What does research chemical grade mean?

It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.

How should SR9009 be stored?

Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.

Network